1
|
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer.
|
Science
|
2009
|
18.40
|
2
|
A phase 2 study of bortezomib in relapsed, refractory myeloma.
|
N Engl J Med
|
2003
|
16.11
|
3
|
Characteristic genome rearrangements in experimental evolution of Saccharomyces cerevisiae.
|
Proc Natl Acad Sci U S A
|
2002
|
4.97
|
4
|
NF-kappa B as a therapeutic target in multiple myeloma.
|
J Biol Chem
|
2002
|
4.94
|
5
|
Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling.
|
Clin Cancer Res
|
2005
|
4.84
|
6
|
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
|
J Clin Oncol
|
2004
|
3.42
|
7
|
Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.
|
J Clin Oncol
|
2004
|
3.02
|
8
|
Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.
|
J Clin Oncol
|
2002
|
2.88
|
9
|
Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.
|
Cancer Res
|
2002
|
2.83
|
10
|
The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.
|
Clin Cancer Res
|
2003
|
2.27
|
11
|
A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.
|
Clin Cancer Res
|
2002
|
2.21
|
12
|
PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis.
|
Mol Cancer Ther
|
2002
|
2.11
|
13
|
Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.
|
Proc Natl Acad Sci U S A
|
2006
|
1.78
|
14
|
Equine infectious anemia virus and the ubiquitin-proteasome system.
|
J Virol
|
2002
|
1.63
|
15
|
Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies.
|
Blood
|
2004
|
1.62
|
16
|
Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926).
|
J Med Chem
|
2009
|
1.58
|
17
|
Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines.
|
Clin Cancer Res
|
2003
|
1.47
|
18
|
Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma.
|
Int J Radiat Oncol Biol Phys
|
2005
|
1.44
|
19
|
Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.
|
J Med Chem
|
2006
|
1.42
|
20
|
Proteasome inhibition ablates activation of NF-kappa B in myocardial reperfusion and reduces reperfusion injury.
|
Am J Physiol Heart Circ Physiol
|
2002
|
1.37
|
21
|
Retroviruses have differing requirements for proteasome function in the budding process.
|
J Virol
|
2003
|
1.34
|
22
|
Analysis of tissue transglutaminase function in the migration of Swiss 3T3 fibroblasts: the active-state conformation of the enzyme does not affect cell motility but is important for its secretion.
|
J Biol Chem
|
2002
|
1.28
|
23
|
Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
|
J Clin Oncol
|
2006
|
1.24
|
24
|
Novel IKK inhibitors: beta-carbolines.
|
Bioorg Med Chem Lett
|
2003
|
1.11
|
25
|
Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts.
|
Mol Cancer Ther
|
2002
|
1.08
|
26
|
Delayed treatment with MLN519 reduces infarction and associated neurologic deficit caused by focal ischemic brain injury in rats via antiinflammatory mechanisms involving nuclear factor-kappaB activation, gliosis, and leukocyte infiltration.
|
J Cereb Blood Flow Metab
|
2003
|
1.08
|
27
|
Semisynthetic cyclopamine analogues as potent and orally bioavailable hedgehog pathway antagonists.
|
J Med Chem
|
2008
|
1.07
|
28
|
Evolution in Saccharomyces cerevisiae: identification of mutations increasing fitness in laboratory populations.
|
Genetics
|
2003
|
1.00
|
29
|
Delayed treatment of ischemia/reperfusion brain injury: extended therapeutic window with the proteosome inhibitor MLN519.
|
Stroke
|
2004
|
0.97
|
30
|
Hsp90 (heat shock protein 90) inhibitor occupancy is a direct determinant of client protein degradation and tumor growth arrest in vivo.
|
J Biol Chem
|
2010
|
0.95
|
31
|
A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma.
|
Leuk Lymphoma
|
2011
|
0.92
|
32
|
The antiproliferative activity of the heat shock protein 90 inhibitor IPI-504 is not dependent on NAD(P)H:quinone oxidoreductase 1 activity in vivo.
|
Mol Cancer Ther
|
2009
|
0.86
|
33
|
Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer.
|
Clin Cancer Res
|
2003
|
0.85
|
34
|
Assays for proteasome inhibition.
|
Methods Mol Med
|
2003
|
0.82
|
35
|
Regiospecific and stereoselective syntheses of (+/-) morphine, codeine, and thebaine via a highly stereocontrolled intramolecular 4 + 2 cycloaddition leading to a phenanthrofuran system.
|
J Am Chem Soc
|
2009
|
0.78
|
36
|
Ty1 insertions in intergenic regions of the genome of Saccharomyces cerevisiae transcribed by RNA polymerase III have no detectable selective effect.
|
FEMS Yeast Res
|
2004
|
0.77
|
37
|
Discovery of (E)-3-((styrylsulfonyl)methyl)pyridine and (E)-2-((styrylsulfonyl)methyl)pyridine derivatives as anticancer agents: synthesis, structure-activity relationships, and biological activities.
|
J Med Chem
|
2014
|
0.77
|
38
|
The pre-clinical absorption, distribution, metabolism and excretion properties of IPI-926, an orally bioavailable antagonist of the hedgehog signal transduction pathway.
|
Xenobiotica
|
2013
|
0.76
|
39
|
Structure of aldehyde reductase in ternary complex with a 5-arylidene-2,4-thiazolidinedione aldose reductase inhibitor.
|
Eur J Med Chem
|
2009
|
0.75
|